329 results on '"Levine, Bruce"'
Search Results
2. Forever in Struggle
3. T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy
4. The Colors of Courage: Gettysburg's Forgotten History: Immigrants, Women, and African Americans in the Civil War's Defining Battle (review)
5. "Your True Marcus": The Civil War Letters of a Jewish Colonel (review)
6. Contract development and manufacturing organization selection: critical considerations that can make or break your cell and gene therapy development
7. A simulation-based comparison of centralized and point-of-care supply chain strategies for autologous cell therapy
8. Beyond youth: Understanding CAR T cell fitness in the context of immunological aging
9. International Society for Cell & Gene Therapy Position Paper: Key considerations to support evidence-based cell and gene therapies and oppose marketing of unproven products
10. Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia
11. Patient access to and ethical considerations of the application of the European Union hospital exemption rule for advanced therapy medicinal products
12. Commercial autologous cell therapy: The value of real-time patient and therapy data
13. A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma
14. Engineering T cells to survive and thrive in the hostile tumor microenvironment
15. Decade-long leukaemia remissions with persistence of CD4+ CAR T cells
16. Advances in engineering and synthetic biology toward improved therapeutic immune cells
17. Adoptive T-cell therapy for Hodgkin lymphoma
18. Advances in automated cell washing and concentration
19. Autologous CD4 T Lymphocytes Modified with a Tat-Dependent, Virus-Specific Endoribonuclease Gene in HIV-Infected Individuals
20. Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer
21. Diagnostic biomarkers to differentiate sepsis from cytokine release syndrome in critically ill children
22. Emerging trends in COVID-19 treatment: learning from inflammatory conditions associated with cellular therapies
23. Accelerating the development of innovative cellular therapy products for the treatment of cancer
24. CAR T-cell product performance in haematological malignancies before and after marketing authorisation
25. The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19
26. CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration
27. Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers
28. T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma
29. A multiscale simulation framework for the manufacturing facility and supply chain of autologous cell therapies
30. Chimeric antigen receptor–T cell therapy manufacturing: modelling the effect of offshore production on aggregate cost of goods
31. Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial
32. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma
33. Retroviral and Lentiviral Safety Analysis of Gene-Modified T Cell Products and Infused HIV and Oncology Patients
34. Introducing Technology to Immigrant Families to Support Early Literacy Development and Two-Generation Learning
35. Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia
36. Monocyte lineage–derived IL-6 does not affect chimeric antigen receptor T-cell function
37. Global Manufacturing of CAR T Cell Therapy
38. Optimization of cGMP purification and expansion of umbilical cord blood–derived T-regulatory cells in support of first-in-human clinical trials
39. Conservatism, Nativism, and Slavery: Thomas R. Whitney and the Origins of the Know-Nothing Party
40. Constitutive and Regulated Expression of Telomerase Reverse Transcriptase (hTERT) in Human Lymphocytes
41. BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia
42. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell
43. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells
44. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
45. Differential Regulation of HIV-1 Fusion Cofactor Expression by CD28 Costimulation of CD4$^+$ T Cells
46. Antiviral Effect and Ex Vivo CD4$^+$ T Cell Proliferation in HIV-Positive Patients as a Result of CD28 Costimulation
47. miR-146b antagomir–treated human Tregs acquire increased GVHD inhibitory potency
48. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia
49. Umbilical cord blood–derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect
50. CCR5-edited [CD4.sup.+] T cells augment HIV-specific immunity to enable post-rebound control of HIV replication
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.